Lite Strategy, Inc. (LITS)
0.9855
+0.01
(+0.52%)
USD |
NASDAQ |
Aug 31, 16:00
Lite Strategy Cash from Operations (TTM) : -10.42M for March 31, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | -10.42M |
| December 31, 2025 | -12.16M |
| September 30, 2025 | -13.90M |
| June 30, 2025 | -20.84M |
| March 31, 2025 | -36.59M |
| December 31, 2024 | -36.25M |
| September 30, 2024 | -43.64M |
| June 30, 2024 | -50.68M |
| March 31, 2024 | -43.78M |
| December 31, 2023 | -52.98M |
| September 30, 2023 | -56.19M |
| June 30, 2023 | -52.48M |
| March 31, 2023 | -56.69M |
| December 31, 2022 | -61.51M |
| September 30, 2022 | -55.81M |
| June 30, 2022 | -48.75M |
| March 31, 2022 | -44.50M |
| December 31, 2021 | -43.19M |
| September 30, 2021 | -30.57M |
| June 30, 2021 | -31.96M |
| March 31, 2021 | 48.40M |
| December 31, 2020 | 53.76M |
| September 30, 2020 | 39.22M |
| June 30, 2020 | 34.26M |
| March 31, 2020 | -42.92M |
| Date | Value |
|---|---|
| December 31, 2019 | -43.96M |
| September 30, 2019 | -30.68M |
| June 30, 2019 | -29.42M |
| March 31, 2019 | -25.11M |
| December 31, 2018 | -20.01M |
| September 30, 2018 | -27.56M |
| June 30, 2018 | -21.30M |
| March 31, 2018 | -20.70M |
| December 31, 2017 | -12.85M |
| September 30, 2017 | -11.85M |
| June 30, 2017 | 3.486M |
| March 31, 2017 | 3.149M |
| December 31, 2016 | -2.842M |
| September 30, 2016 | -3.323M |
| June 30, 2016 | -17.86M |
| March 31, 2016 | -21.12M |
| December 31, 2015 | -24.88M |
| September 30, 2015 | -27.10M |
| June 30, 2015 | -28.07M |
| March 31, 2015 | -27.18M |
| December 31, 2014 | -24.10M |
| September 30, 2014 | -22.12M |
| June 30, 2014 | -19.45M |
| March 31, 2014 | -16.37M |
| December 31, 2013 | -13.93M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| SELLAS Life Sciences Group, Inc. | -28.42M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |
| Savara, Inc. | -110.38M |